Investors who lost money from Savara Inc. (SVRA) have chance to lead securities fraud lawsuit

The Law Offices of Frank R. Cruz is investigating potential securities fraud claims on behalf of investors of Savara Inc. (NASDAQ: SVRA). The investigation focuses on whether the Company issued misleading information to investors, thereby violating federal securities laws.

Savara is a clinical-stage pharmaceutical company that focuses on the development of novel therapies for the treatment of rare respiratory diseases. The Company’s lead product candidate is Molgradex, which is being developed for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease.

On October 2, 2020, Savara announced that the Company will no longer pursue the development of Molgradex for aPAP following disappointing results from a Phase 3 study. This news caused the Company’s stock price to plummet by nearly 73% on October 5, 2020.

The Law Offices of Frank R. Cruz is investigating whether Savara and its executives made false and/or misleading statements regarding the prospects of Molgradex and its potential for treating aPAP. If it is determined that the Company misled investors, causing them to suffer financial losses, then investors may have a viable securities fraud claim.

Investors who purchased shares of Savara and suffered financial losses are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights. It is important to note that filing a securities fraud class action lawsuit is a way for investors to seek recourse for any losses incurred due to potentially misleading statements made by a Company and its executives.

The Law Offices of Frank R. Cruz is experienced in handling securities fraud cases and has a track record of fighting for the rights of investors. If you believe that you have been a victim of securities fraud in connection with your investment in Savara, do not hesitate to reach out for a consultation.

In conclusion, the investigation into potential securities fraud claims against Savara Inc. is ongoing, with a focus on determining whether the Company misled investors regarding the prospects of its lead product candidate, Molgradex. Investors who suffered financial losses as a result of potentially misleading statements made by Savara and its executives may have legal recourse through a securities fraud class action lawsuit. Contact The Law Offices of Frank R. Cruz to discuss your legal rights and options.

Remember, it is important to seek guidance from experienced securities fraud attorneys who can help you navigate the complexities of such cases and fight for your rights as an investor.